Arrowhead Pharmaceuticals Hits Day High with 8.17% Surge in Stock Price

Arrowhead Pharmaceuticals, Inc. has experienced significant activity today, with the stock rising by 8.17% and reaching an intraday high of USD 31.62. This notable performance stands out against the backdrop of the broader market, as the S&P 500 has seen a slight decline of 0.1% on the same day.
In terms of performance metrics, Arrowhead Pharmaceuticals has demonstrated impressive gains over various time frames. Over the past month, the stock has surged by 141.83%, significantly outperforming the S&P 500's 2.33% increase. Year-to-date, the stock has risen by 67.61%, while the S&P 500 has gained 12.22%. However, the company has faced challenges in the longer term, with a 5-year performance decline of 10.0% compared to the S&P 500's robust 96.61% growth.

Arrowhead Pharmaceuticals operates within the Pharmaceuticals & Biotechnology industry, holding a market capitalization of USD 3,756 million. Despite its recent gains, the company has reported a negative EBITDA and a return on equity of -30.51%, indicating ongoing financial challenges.